Abstract
The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Current HIV Research
Title: The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication
Volume: 5 Issue: 4
Author(s): Peter Bergman, Lilian Walter-Jallow, Kristina Broliden, Birgitta Agerberth and Johan Soderlund
Affiliation:
Keywords: Antimicrobial peptide, cathelicidin, innate immunity, HIV-1, LL-37, FPRL-1
Abstract: The antimicrobial peptide LL-37 is the only cathelicidin that has been described in humans. LL-37 exerts chemotactic, immunomodulatory and angiogenic effects; activities that are mediated through binding to the formyl peptide receptor like (FPRL)-1 receptor. Agonistic ligation of FPRL-1 can also induce down-regulation of HIV-1 chemokine receptors and reduce susceptibility to HIV-1 infection in vitro. Therefore, we have evaluated the capacity of LL-37 to inhibit HIV-1 infection in vitro. Here we demonstrate that LL-37 inhibits HIV-1 replication in PBMC, including primary CD4+ T cells. This inhibition was readily reproduced using various HIV-1 isolates without detectable changes in the target cell expression of HIV-1 chemokine receptors. Accordingly, the HIV-1 inhibitory effect was shown to be independent of FPRL-1 signalling. Given the epithelial expression of LL-37, it may contribute to the local protection against HIV-1 infection.
Export Options
About this article
Cite this article as:
Peter Bergman , Lilian Walter-Jallow , Kristina Broliden , Birgitta Agerberth and Johan Soderlund , The Antimicrobial Peptide LL-37 Inhibits HIV-1 Replication, Current HIV Research 2007; 5 (4) . https://dx.doi.org/10.2174/157016207781023947
DOI https://dx.doi.org/10.2174/157016207781023947 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Drug Delivery & Formulation Practical Considerations in the Development of Hemoglobin-Based Oxygen Therapeutics
Current Drug Discovery Technologies The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Human Defensins: Turning Defense into Offense?
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on Regenerative Medicine Recent Patents and New Strategies in the Treatment of Psoriasis
Recent Patents on Anti-Infective Drug Discovery Acute Myocardial Infarction in Systemic Mastocytosis: Case Report With Literature Review on the Role of Inflammatory Process in Acute Coronary Syndrome
Current Cardiology Reviews Mechanisms of Thrombosis, Available Treatments and Management Challenges Presented by Thromboangiitis Obliterans
Current Medicinal Chemistry PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
Current Pharmaceutical Design Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Magnesium-dependent Phosphatase (MDP) 1 is a Potential Suppressor of Gastric Cancer
Current Cancer Drug Targets Expression, Purification and Evaluation of Diagnostic Potential and Immunogenicity of Dengue Virus Type 3 Domain III Protein
Protein & Peptide Letters Scientific Prediction and Prophetic Patenting in Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Tolfenamic Acid Prevents Amyloid β-induced Olfactory Bulb Dysfunction In Vivo
Current Alzheimer Research A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Primary Characterization and Evaluation of Anti Ulcerogenic Activity of an Aqueous Extract from Callus Culture of Cereus peruvianus Mill. (Cactaceae)
Current Pharmaceutical Biotechnology The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Illicium verum Extract Exhibited Anti-inflammatory Action in Rodents
Letters in Drug Design & Discovery